CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.94−0.05 (-2.27%)
Close on Nov 17, 2026Market cap $422.73MP/E –Yield –
CytomX Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
CytomX Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$82.41M. For fiscal 2025 it was -$75.59M. The highest annual figure on record is $170.37M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$75.59M | – |
| FY2024 | Dec 31, 2024 | -$86.23M | – |
| FY2023 | Dec 31, 2023 | -$56.04M | – |
| FY2022 | Dec 31, 2022 | -$110.79M | – |
| FY2021 | Dec 31, 2021 | -$119.03M | -2363.4% |
| FY2020 | Dec 31, 2020 | $5.26M | – |
| FY2019 | Dec 31, 2019 | -$140.48M | – |
| FY2018 | Dec 31, 2018 | -$75.52M | -144.3% |
| FY2017 | Dec 31, 2017 | $170.37M | – |
| FY2016 | Dec 31, 2016 | -$2.03M | – |
| FY2015 | Dec 31, 2015 | -$27.42M | -186.2% |
| FY2014 | Dec 31, 2014 | $31.80M | – |
| FY2013 | Dec 31, 2013 | -$8.01M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$18.07M | – |
| Q1 FY2026 | Mar 31, 2026 | -$25.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$20.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.55M | – |
| Q1 FY2024 | Mar 31, 2024 | -$26.05M | -378.6% |
| Q4 FY2023 | Dec 31, 2023 | -$21.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.24M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.18M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.39M | – |
| Q3 FY2022 | Sep 30, 2022 | -$33.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$41.31M | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$29.70M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.20M | -129.0% |
| Q1 FY2021 | Mar 31, 2021 | -$29.94M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.43M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.68M | – |
| Q2 FY2020 | Jun 30, 2020 | $97.10M | – |
| Q1 FY2020 | Mar 31, 2020 | -$49.74M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.48M | – |
| Q3 FY2019 | Sep 30, 2019 | -$23.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$48.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$39.03M | – |
| Q4 FY2018 | Dec 31, 2018 | -$28.74M | -230.6% |
| Q3 FY2018 | Sep 30, 2018 | -$5.55M | – |
| Q2 FY2018 | Jun 30, 2018 | -$26.62M | -115.4% |
| Q1 FY2018 | Mar 31, 2018 | -$14.61M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.00M | +1036.5% |
| Q3 FY2017 | Sep 30, 2017 | -$5.74M | – |
| Q2 FY2017 | Jun 30, 2017 | $173.20M | – |
| Q1 FY2017 | Mar 31, 2017 | -$19.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.94M | – |
| Q3 FY2016 | Sep 30, 2016 | -$14.18M | – |
See a number that looks wrong?